FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * CMEA VENTURES VI LP   2. Issuer Name and Ticker or Trading Symbol INTERMOLECULAR INC [IMI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1 LETTERMAN DR., BLDG. C, SUITE CM500 3. Date of Earliest Transaction (Month/Day/Year) 06/13/2013 (Street) SAN FRANCISCO, CA 94129 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/13/2013   J(1)   999,529 D $ 0 6,375,971 D (2)   Common Stock 06/13/2013   J(3)   22,891 D $ 0 150,052 D (4)   Common Stock 06/13/2013   J(5)   20,218 D $ 0 0 D (6)   Common Stock 06/14/2013   S   3,546 D $ 7.2525 (7) 0 D (8)   Common Stock 06/14/2013   S   3,546 D $ 7.2808 (9) 0 D (10)   Common Stock 07/05/2013   S   3,146 D $ 7.4227 (11) 400 D (12)   Common Stock 07/09/2013   S   400 D $ 7.3375 (13) 0 D (12)   Common Stock 09/09/2013   J(1)   999,529 D $ 0 5,376,442 D (2)   Common Stock 09/09/2013   J(3)   22,891 D $ 0 127,161 D (4)   Common Stock 09/09/2013   J(5)   20,218 D $ 0 0 D (6)   Common Stock 09/12/2013   S   3,546 D $ 5.6131 (14) 0 D (8)   Common Stock 03/12/2014   J(1)   999,529 D $ 0 4,376,913 D (2)   Common Stock 03/12/2014   J(3)   22,891 D $ 0 104,270 D (4)   Common Stock 03/12/2014   J(5)   20,218 D $ 0 0 D (6)   Common Stock 03/13/2014   S   1,528 D $ 2.7179 (15) 2,018 D (8)   Common Stock 03/14/2014   S   1,307 D $ 2.7537 (16) 711 D (8)   Common Stock 03/14/2014   S   1,251 D $ 2.7548 (17) 5,841 D (10)   Common Stock 03/17/2014   S   1,241 D $ 2.7475 (18) 4,600 D (10)   Common Stock 03/18/2014   S   711 D $ 2.75 0 D (8)   Common Stock 03/19/2014   S   1,800 D $ 2.8336 (19) 2,800 D (10)   Common Stock 03/20/2014   S   1,800 D $ 2.8636 (20) 1,000 D (10)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
CMEA VENTURES VI LP 1 LETTERMAN DR., BLDG. C, SUITE CM500 SAN FRANCISCO, CA 94129	X	X
CMEA Ventures VI GmbH & Co. KG 1 LETTERMAN DR., BLDG. C, SUITE CM500 SAN FRANCISCO, CA 94129	X	X
CMEA Ventures VI Management, L.P. 1 LETTERMAN DR., BLDG. C, SUITE CM500 SAN FRANCISCO, CA 94129	X	X
Collier David J 1 LETTERMAN DR., BLDG. C, SUITE CM500 SAN FRANCISCO, CA 94129	X	X
Sohail Faysal A. 1 LETTERMAN DR., BLDG. C, SUITE CM500 SAN FRANCISCO, CA 94129	X	X
Watson James F 1 LETTERMAN DR., BLDG. C, SUITE CM500 SAN FRANCISCO, CA 94129	X	X

Signatures

/s/ James F. Watson, General Partner of CMEA Ventures VI Management, L.P., General Partner of CMEA Ventures VI, L.P.		06/25/2014
**Signature of Reporting Person		Date
/s/ James F. Watson, General Partner of CMEA Ventures VI Management, L.P., managing limited partner of CMEA Ventures VI GmbH & Co. KG		06/25/2014
**Signature of Reporting Person		Date
/s/ James F. Watson, General Partner of CMEA Ventures VI Management, L.P.		06/25/2014
**Signature of Reporting Person		Date
/s/ David J. Collier		06/25/2014
**Signature of Reporting Person		Date
/s/ Faysal A. Sohail		06/25/2014
**Signature of Reporting Person		Date
/s/ James F. Watson		06/25/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Distribution of shares in kind by CMEA Ventures VI, L.P. ("CMEA VI") on a pro rata basis to its partners.
(2)	The shares are directly held by CMEA VI. The general partner of CMEA VI is CMEA Ventures VI Management, L.P. ("CMEA GP"). The general partners of CMEA GP include Faysal Sohail ("Sohail"), James Watson ("Watson") and David Collier ("Collier", and collectively with Sohail and Watson, the "General Partners") and, as such, each of CMEA GP and the General Partners exercises shared voting and investment power over the shares held of record by CMEA VI. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
(3)	Distribution of shares in kind by CMEA Ventures VI GmbH & Co. KG ("CMEA VI GmbH") on a pro rata basis to its partners.
(4)	The shares are directly held by CMEA VI GmbH. The managing limited partner of CMEA VI GmbH is CMEA GP and, as such, each of CMEA GP and the General Partners exercises shared voting and investment power over the shares held of record by CMEA VI GmbH. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
(5)	CMEA GP received shares distributed in kind by CMEA VI and CMEA VI GmbH on a pro rata basis to each such Reporting Person's partners and, in turn, made a distribution of shares in kind on a pro rata basis to its own partners. Each of the Reporting Persons disclaims beneficial ownership of CMEA GP's shares except to the extent of their pecuniary interest therein, if any.
(6)	Each General Partner received shares distributed in kind by CMEA GP on a pro rata basis to its partners.
(7)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.30, inclusive. Collier undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(8)	The shares are directly held by Collier.
(9)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.265 to $7.30, inclusive. Watson undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(10)	The shares are directly held by Watson.
(11)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.36 to $7.45, inclusive. Sohail undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(12)	The shares are directly held by Sohail.
(13)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.29 to $7.37, inclusive. Sohail undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(14)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.58 to $5.65, inclusive. Collier undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(15)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.69 to $2.78, inclusive. Collier undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(16)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.79, inclusive. Collier undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(17)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.79, inclusive. Watson undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(18)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.82, inclusive. Watson undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(19)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.825 to $2.89, inclusive. Watson undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(20)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.89, inclusive. Watson undertakes to provide to Intermolecular, Inc., any security holder of Intermolecular, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.